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Abstract
Introduction c-erbB2 (also known as HER-2/neu) and
topoisomerase IIα  are frequently overexpressed in breast
cancer. The aim of the study was to analyze retrospectively
whether the expression of c-erbB2 and topoisomerase IIα
protein influences the long-term outcome of patients with
primary breast cancer.
Methods In this study c-erbB2 and topoisomerase IIα  protein
were evaluated by immunohistochemistry in formalin-fixed
paraffin-embedded tissue from 225 samples of primary breast
cancer, obtained between 1986 and 1998. The prognostic
value of these markers was analyzed.
Results Of 225 primary breast tumor samples, 78 (34.7%)
showed overexpression of either c-erbB2 (9.8%) or
topoisomerase IIα  protein (24.9%), whereas in 21 tumors
(9.3%) both proteins were found to be overexpressed. Patients
lacking both c-erbB2 and topoisomerase IIα  overexpression had
the best long-term survival. Overexpression of either c-erbB2 or
topoisomerase IIα  was associated with shortened survival,
whereas patients overexpressing both c-erbB2 and
topoisomerase IIα  showed the worst disease outcome (P  <
0.0001). Treatment with anthracyclines was not capable of
reversing the negative prognostic impact of topoisomerase IIα
or c-erbB2 overexpression.
Conclusion The results of this exploratory study suggest that
protein expression of c-erbB2 and topoisomerase IIα  in primary
breast cancer tissues are independent prognostic factors and
are not exclusively predictive factors for anthracycline response
in patients with primary breast cancer.
Introduction
The protein expression status of c-erbB2 and, more recently,
of topoisomerase IIα  has been implicated in the prediction of
clinical outcome and response to chemotherapy in breast can-
cer [1-5]. Gene amplification is the predominant but not exclu-
sive mechanism causing abnormal expression in these tumors
(reviewed in [6]). c-erbB2 is localized on chromosome 17q12-
21 and encodes for a transmembrane tyrosine kinase receptor
protein. This highly glycosylated protein is a member of the
epidermal growth factor receptor (EGFR; HER) family [7] and
is expressed on most cells of epithelial origin. In vitro, overex-
pression of c-erbB2 in epithelial cells ultimately affects the reg-
ulation of cell proliferation, of apoptotic pathways, of motility,
and of adhesion (overview in [8]). Accordingly, numerous stud-
ies have found that both c-erbB2 amplification and c-erbB2
protein overexpression predicted disease outcome in patients
with localized breast cancer (overview in [9]).
The α  isoform of topoisomerase is a key enzyme in DNA repli-
cation and also a target for various chemotherapeutic agents
such as anthracyclines or epipodophyllotoxins. The gene is
located in close proximity to the c-erbB2 gene on chromo-
some 17q21 and encodes for a 170-kilodalton protein. The
enzyme catalyzes the unwinding of the DNA to a partlyBreast Cancer Research    Vol 7 No 3    Fritz et al.
R375
uncoiled form by inducing single-stranded breaks on both
DNA strands. These breaks allow the passage of double-
stranded DNA through the gap [10]. Anthracyclines, one of
the most widely used class of cytotoxic agents for the treat-
ment of breast cancer, inhibit topoisomerase IIα  by trapping
the DNA strand break intermediates, leading to persistent
DNA cleavage.
An important role for the outcome of patients with breast can-
cer has been proposed both for the c-erbB2 and topoisomer-
ase IIα  protein [11]. Interestingly, a high percentage of primary
breast tumors with c-erbB2 amplification also show a gene
copy number alteration of other genes such as topoisomerase
IIα  located near to the c-erbB2 locus on chromosome 17
[12,13]. Although the appearance of topoisomerase IIα  gene
alterations (amplification or deletion) was exclusively seen in c-
erbB2-amplified breast tumors [3,12-14], data on the protein
expression status of these two genes in breast tumor samples
are controversial. Jarvinen and colleagues report a high corre-
lation of c-erbB2 and topoisomerase IIα  protein expression
[15]. In contrast, in a recently published study it was observed
that in 14 of 33 topoisomerase IIα -amplified tumors, topoi-
somerase IIα  protein was present in less than 10% of tumor
cells [16]. Another study showed that topoisomerase IIα  over-
expression is present in 30% of c-erbB2 non-amplified tumors
[17]. From these studies it has to be concluded that gene
amplification is only one of many mechanisms causing high
intracellular levels of the topoisomerase IIα  protein. This is in
concordance with the fact that expression of topoisomerase
IIα  is regulated on multiple levels, including transcriptional,
translational, and post-translational mechanisms [18]. These
data suggest that the expression of topoisomerase IIα  and c-
erbB2 protein might independently predict the clinical out-
come in breast cancer. We therefore analyzed the prognostic
impact of the protein expression status of both c-erbB2 and
topoisomerase IIα  in a large cohort of patients with primary
breast cancer.
Materials and methods
Patients and pathological data
Tumor tissue was analyzed for protein expression of c-erbB2
and topoisomerase IIα  from 225 patients with primary invasive
breast cancer who underwent surgery from 1986 to 1998 at
the Department of Gynaecology, Robert Bosch Hospital,
Stuttgart, Germany. The local ethics committee was informed
and gave consent. The patient database was anonymized to
guarantee privacy. The tissues were formalin-fixed and paraf-
fin-embedded in accordance with standard methods. Histo-
logical classification was performed by following the
recommendations of the World Health Organization [19].
Three histological types were discriminated: invasive ductal,
invasive lobular, and all other specified tumor types such as
tubular carcinoma. The pathological reports included tumor
size, palpable nodes, metastasis, grading, estrogen receptor
status, and progesterone receptor status.
Immunohistochemical methods
For immunocytochemistry, 3 µm sections were deparaffinized
in xylene for 30 min and rinsed in 100%, 96% and 70% etha-
nol. Sections were then subjected to antigen retrieval by
immersion in citrate buffer (pH 6.0) preheated to 99°C for 40
min. Endogenous peroxidase was blocked by incubation in
3% H2O2 in methanol for 30 min, followed by rinsing in Tris-
buffered saline containing Tween 20. Immunohistochemical
staining was performed with the EnVision™+ System Kit
(DakoCytomation, Glostrup, Denmark). Afterwards, the sec-
tions were incubated overnight in a humidity chamber with the
monoclonal primary antibody against topoisomerase IIα
(DakoCytomation; dilution 1:100) and c-erbB2 (clone CB11;
Novocastra, Newcastle, UK; dilution 1:10) followed by incuba-
tion for 30 min with a dextran polymer conjugated with horse-
radish peroxidase enzyme and with goat anti-rabbit antibody.
The antigen–antibody immunoreaction was revealed with 3,3'-
diaminobenzidinetetrahydrochloride as the chromogen, and
the slides were counterstained with hematoxylin.
Immunohistochemical analysis of c-erbB2 (HER-2/neu) pro-
tein was also performed with HercepTest™ (DakoCytomation)
on an automated immunostaining system (Dako Autostainer),
with the use of the manufacture's detection procedures. This
procedure was part of the primary diagnostic process. For
each case c-erbB2 was assessed twice: once by immunos-
taining with CB11 and once by herceptin staining. Estrogen
and progesterone receptor statuses were assessed during the
first years (up to 1990) by charcoal dextran method [20], sam-
ples examined after this time were analyzed by
immunohistochemistry.
Scoring interpretation
The scoring system proposed by HercepTest was used for the
interpretation of the immunoreactivity of both CB11 and Her-
cepTest, distinguishing between no staining (0), weakly (1+),
moderate (2+), and strong membrane staining (3+). Cytoplas-
mic staining was ignored.
Only nuclear staining was considered for topoisomerase IIα .
Immunostaining frequency of the tumor cells was scored sub-
jectively on a scale of 1 to 4 (1, 0 to 5% positive tumor cells;
2, 6 to 25%; 3, 26 to 75%; 4, more than 75%), as proposed
by Sandri and colleagues [21]. Finally, after cut-off analysis we
stratified the results as negative for less than 25% tumor cells
and positive for all cases in which more than 25% of tumor
cells stained positive for topoisomerase IIα . For hormone
receptor status we classified the tumor as positive if there was
more than 15 fmol per mg of protein (charcoal dextran
method) or with a score of more than 1
(immunohistochemistry).
Statistical methods
Descriptive statistical analysis was performed with commer-
cially available software packages (SPSS, version 11.1Available online http://breast-cancer-research.com/content/7/3/R374
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(SPSS GmbH, Munich, Germany) and R, version 2.0 http://
www.r-project.org). We used the Kaplan–Meier estimator for
univariate statistical analysis and the Cox regression model for
multivariate analysis. P < 0.05 was considered to be signifi-
cant. A log-rank test was applied for assessing statistical dif-
ferences between survival curves. The χ 2 test was used to
investigate the relationship between topoisomerase IIα
expression and histological grading and to analyze the associ-
ation between topoisomerase IIα  and c-erbB2 overexpression
with hormone receptor status or stage.
Results
Patients
Tissue samples of 225 patients were analyzed for protein
expression of c-erbB2 or topoisomerase IIα . The characteris-
tics of these patients and tumors are summarized in Table 1.
The distribution of stage, tumor size, nodal status, histological
grading, and receptor status is in conformity with that
observed in published randomized clinical trials (Table 2;
reviewed in [22]). All patients had received appropriate local
surgical treatment. Adjuvant medical therapy was given to 143
patients: 61 received hormone therapy; 82 were treated with
adjuvant chemotherapy, either anthracycline-containing (46
patients) or anthracycline-free (36 patients; Table 3) regimens.
After a mean follow-up period of 67 months, 136 patients
were alive and 89 deaths had been recorded. The death of 68
patients (30%) was documented to have been caused by
breast cancer (Table 1). Survival at 1 year was 95.73%, at 3
years 85.45%, at 5 years 74.26%, and at 10 years 63.69% for
all patients. Again, this survival rate is comparable to that pub-
lished for similar patient populations [22].
Prognostic impact of c-erbB2 overexpression
Tumors with an immunoreactive score exceeding 2 or 3 were
considered to overexpress c-erbB2. Accordingly, 43 (19.1%)
of the patients showed overexpression of this oncogene.
Patients with c-erbB2 overexpression showed a similar distri-
bution of age, stage, histological criteria, and receptor status
to that of the c-erbB2 negative subgroup (data not shown).
However, the former patients were characterized by a signifi-
cantly inferior survival in a univariate statistical analysis (log
rank 17.94; P < 0.0001). The median overall survival time of
patients with tumors overexpressing c-erbB2 was 55 months,
with a 5-year survival rate of 46.0%. In contrast, median sur-
vival time was not reached in the c-erbB2 negative group. The
5-year survival in this group was 78.3% (Fig. 1a). Patients with
c-erbB2-overexpressing tumors received no significant benefit
from anthracycline-based adjuvant therapy, and even had the
worst prognosis of all groups analyzed (log rank 10.17; P =
0.001; see below).
Impact of topoisomerase IIα  expression
Topoisomerase IIα  staining was strictly nuclear and highly var-
iable between different tissue samples. To study the impact of
different levels of overexpression of topoisomerase IIα  protein,
we analyzed the survival curves of patients with 0 to 5%, 6 to
25%, 26 to 75% and more than 75% positively stained cells
(data not shown). These analyses demonstrated that the sur-
vival of patients was significantly inferior in cases with high
topoisomerase IIα  expression in more than 25% of the cells.
Therefore, for further analysis overexpression was defined as
more than 25% positively stained tumor cells. A subgroup of
77 patients (34.2%) had tumors overexpressing topoisomer-
ase IIα . As shown in Fig. 1b, these patients had a significantly
inferior survival (median 80 months; 5-year survival rate
Table 1
Characteristics of patients and tumors
Characteristic Value
Number of patients 225
Age, years (median (range)) 56 (29–88)
Time to relapse, months (median (range))a 25 (0–179)
Alive without disease 123
Relapse 23
Disease status unknown 3
Alive (censored) 136
Death 89
By tumor 68
By unknown causes 8
Not tumor-related (censored) 13
aOnly cases with recurrence are included in this calculation.Breast Cancer Research    Vol 7 No 3    Fritz et al.
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54.4%) in a univariate Kaplan–Meier analysis compared with
those without topoisomerase IIα  overexpression (median not
reached; 5-year survival rate 80.3%; log rank 15.59, P  =
0.0001). The proportion of tumors expressing topoisomerase
IIα  increased with histological grading (χ 2 test, P < 0.001).
The fraction of patients with hormone-receptor-positive tumors
was significantly higher in samples without topoisomerase IIα
overexpression (χ 2 test, P = 0.004).
The prognostic impact of topoisomerase IIα  expression was
dependent on stage: whereas stage IV patients had an identi-
cally poor outcome regardless of topoisomerase IIα  expres-
sion (not shown), stage II and III patients had a significantly
lower survival rate when topoisomerase IIα  was highly
expressed (log rank 9.35, P = 0.002 for WHO stage II; log
rank 4.76, P = 0.029 for WHO stage III; Fig. 2a). In stage I
patients a survival difference of similar magnitude was not sta-
tistically significant, probably because of the small sample size
(Fig. 2a).
Expression of topoisomerase IIα  added prognostic information
to histological grading. The analysis was restricted to grade 2
and 3 tumors, because only a few deaths were observed in
patients with grade 1 disease. The survival of patients with
tumors expressing topoisomerase IIα  was inferior in both
grade 2 tumors (log rank 5.08; P < 0.05) and grade 3 tumors
(log rank 7.86; P = 0.005; Fig. 2b).
In addition, the prognostic impact of topoisomerase IIα  expres-
sion was clearly dependent on the steroid hormone receptor
status of the tumors: no significant difference was observed in
patients with tumors negative for estrogen or progesterone
receptor (log rank 0.94; P = 0.33; Fig. 3, right panel) whereas
detection of topoisomerase IIα  in more than 25% of tumor
cells identified a subgroup with poor prognosis in receptor-
positive breast cancer (log rank 12.0; P = 0.0005; Fig. 3, left
panel).
We further studied whether the prognostic impact of topoi-
somerase IIα  expression was restricted to patients receiving
either non-anthracycline-containing or anthracycline-contain-
ing regimens for adjuvant treatment. By analogy with the
results obtained with c-erbB2-overexpressing tumors (Fig.
4b), treatment with anthracyclines was not capable of
reversing the negative prognostic impact of topoisomerase IIα
expression (log rank 4.74; P = 0.02; Fig. 4a).
Coexpression of c-erbB2 and topoisomerase IIα
The subgroups overexpressing c-erbB2 and topoisomerase
IIα  were overlapping but not identical. One hundred and
twenty-six tumors (56%) showed neither c-erbB2 nor topoi-
somerase IIα  overexpression. Fifty-six (25%) patients had
tumors overexpressing topoisomerase IIα  only; 22 (9.8%)
showed only c-erbB2 overexpression. Twenty-one (9.3%)
tumors showed increased staining for both proteins. None of
these groups differed significantly with regard to clinical stage
(Table 4). However, a statistically significantly higher propor-
tion of hormone-receptor-negative cancers was observed in
the group overexpressing one or both proteins studied (χ 2 test,
P = 0.006; Table 4). A survival analysis of these four groups
demonstrated an independent negative prognostic impact of
either overexpression. As shown in Fig. 5, patients with breast
cancer lacking overexpression of both c-erbB2 and
topoisomerase IIα  had the best long-term prognosis (the
median survival time was not reached; the 5-year survival rate
was 84.4%). Overexpression of either c-erbB2 or topoisomer-
ase IIα  was associated with intermediate survival (for c-erbB2-
overexpressing tumors the median survival time was 68
months and the 5-year survival rate was 57.7%; for topoi-
somerase IIα -overexpressing cases the median survival time
was 104 months and the 5-year survival rate was 63.7%).
Figure 1
Overall survival of breast cancer patients with regard to c-erbB2 and topoisomerase IIα  protein expression Overall survival of breast cancer patients with regard to c-erbB2 and topoisomerase IIα  protein expression. (a) Patients with (solid line) or without 
(dashed line) c-erbB2 protein overexpression. The difference was significant in univariate statistical analysis (log rank 17.94; P < 0.0001). (b) Signif-
icant difference of survival time of patients with tumors positive for topoisomerase IIα  protein in more than 25% of tumor cells (solid line) versus 
patients with tumors with less than 25% topoisomerase IIα -positive cells (dashed line) (log rank 15.59; P = 0.0001).Available online http://breast-cancer-research.com/content/7/3/R374
R378
Figure 2
Prognostic impact of topoisomerase IIα  protein expression with regard to stage and grading Prognostic impact of topoisomerase IIα  protein expression with regard to stage and grading. Patients with tumors positive for topoisomerase IIα  in 
more than 25% of tumor cells (solid lines) were compared with those having tumors expressing topoisomerase IIα  in less than 25% of cells (dashed 
lines) with regard to the stage (a) and the grading (b) of the tumor. The difference was significant in tumors of stage 2 and 3 (P < 0.05) and in grade 
2 and 3 tumors (P < 0.05).
Figure 3
Prognostic impact of topoisomerase IIα  protein expression with regard to hormone status Prognostic impact of topoisomerase IIα  protein expression with regard to hormone status. Patients with tumors positive for topoisomerase IIα  in 
more than 25% of tumor cells (solid lines) were compared with those having tumors expressing topoisomerase IIα  in less than 25% of cells (dashed 
lines) with regard to the hormone status. The difference was significant in tumors positive for estrogen receptor or progesterone receptor (log rank 
12.0; P = 0.0005).Breast Cancer Research    Vol 7 No 3    Fritz et al.
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Those patients overexpressing both proteins had the worst
outcome, with a median survival of 45 months and a 5-year
survival rate of 33.0% (log rank 29.71; P < 0.0001; Fig. 5).
In a multivariate Cox regression model (Tables 5 and 6), tumor
stage, estrogen receptor, topoisomerase IIα , and c-erbB2 all
independently predicted disease-related death. Subsequent
Table 2
Clinical characteristics of study patients (N = 225)
Variable n (%)
Stage (n = 214)
I 40 (18.7)
II 113 (52.8)
III 53 (24.8)
IV 8 (3.7)
T (n = 222)
T1 59 (26.6)
T2 106 (47.7)
T3 27 (12.2)
T4 30 (13.5)
N (n = 222)
N0 94 (42.3)
N1 112 (50.5)
N2-3 16 (7.2)
Grading (n = 220)
G1/G2 151 (68.6)
G3 69 (31.4)
Histology (n = 225)
Ductal 175 (77.8)
Lobular 22 (9.8)
All other subtypes 28 (12.4)
Menopausal (n = 163)
Premenopausal 43 (26.4)
Postmenopausal 120 (73.6)
ER (n = 212)
Positive 135 (63.7)
Negative 77 (36.3)
PR (n = 211)
Positive 127 (60.2)
Negative 84 (39.8)
Metastasis (n = 218)
Negative 210 (96.3)
Positive 8 (3.7)
ER, estrogen receptor; N, palpable nodes; PR, progesterone receptor; T, tumor size.Available online http://breast-cancer-research.com/content/7/3/R374
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inclusion of grading was far beyond statistical significance
(Table 5). Adding the interaction term topoisomerase IIα  by
grading (topoisomerase IIα  × grading; Table 5) seems worth
consideration. However, in a Wald statistics grading together
with the last-mentioned interaction term failed to reach signifi-
cance (P = 0.11). Models containing in addition interactions
of c-erbB2 by grading (c-erbB2 × grading; Table 5) and c-
erbB2 by topoisomerase IIα  (c-erbB2 × topoisomerase IIα ;
Table 5) are not significantly superior. The last two interaction
terms are therefore not included in the final model as pre-
sented in Table 6.
Discussion
Overexpression of c-erbB2 and topoisomerase IIα  independ-
ently predicts poor survival in this retrospective series of
patients. Topoisomerase IIα  and c-erbB2 were found to be
overexpressed in overlapping but distinct subgroups of
patients. Moreover, the prognostic impact of topoisomerase
IIα  overexpression seems to be independent of other prognos-
tic variables in a multivariate analysis and makes the prognosis
significantly worse in both c-erbB2-positive and c-erbB2-neg-
ative patients. In addition, the prognostic impact of topoi-
somerase IIα  overexpression is dependent on the steroid
receptor status. The results of this study suggest that
Table 3
Medical treatment for primary breast cancer in the study patients (N = 198)
Therapy type Intervention n (%)
Adjuvant hormone therapy No hormone therapy 137 (69.2)
Tamoxifen 61 (30.8)
Adjuvant chemotherapy Anthracycline-containing regimens 46 (23.2)
Anthracycline-free regimens 36 (18.2)
No chemotherapy 116 (58.6)
No adjuvant therapy 55 (27.8)
Figure 4
Survival of patients receiving either non-anthracycline-based therapy or anthracycline-based chemotherapy Survival of patients receiving either non-anthracycline-based therapy or anthracycline-based chemotherapy. (a) The difference between patients with 
less than 25% positive cells for topoisomerase IIα  (dashed lines) and more than 25% positive cells (solid lines) was significant for both patient 
groups (P < 0.05). (b) Significant difference between patients with (solid line) or without (dashed line) c-erbB2 overexpression in the group of 
patients receiving non-anthracycline-based adjuvant therapy (left panel; P = 0.002) or an anthracycline-containing regimen (right panel; P = 0.001)Breast Cancer Research    Vol 7 No 3    Fritz et al.
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anthracycline treatment is not capable of reversing the nega-
tive prognostic influence of topoisomerase IIα  or c-erbB2
expression.
Recent reports have studied the interaction between topoi-
somerase IIα  expression and pathological variables, chemo-
therapy response, and the proliferation rate of breast cancer.
However, only very limited series reported a long-term out-
come of patients with primary breast cancer depending on
topoisomerase IIα . Di Leo and colleagues [2] studied patients
participating in a randomized clinical trial comparing CMF
(cyclophosphamide, methotrexate, and 5-flourouracil) with an
anthracycline-containing regimen. The subgroup of patients
with  topoisomerase IIα   amplification did not do obviously
more badly than the remaining patients. However, the out-
come was strongly dependent on the adjuvant therapy
applied. Another series measuring topoisomerase IIα  protein
by immunohistochemistry showed a significantly adverse influ-
ence of topoisomerase IIα  expression of a similar magnitude to
that in our study [23]. Durbecq and colleagues [16] have
shown that measurement of protein expression and gene
amplification each identify different subsets of patients. These
data suggest that detection of the protein might be better cor-
related with the biological properties of the tumor and
therefore might predict the clinical outcome more precisely
than genetic analysis. The data in our study support the view
that protein expression of topoisomerase IIα  is a relevant fac-
tor predicting long-term prognosis in patients with newly diag-
nosed breast cancer independent of c-erbB2.
Treatment of cell lines with anthracyclines was less effective in
cells with a low expression of topoisomerase IIα  [24,25]. A ret-
rospective subgroup analysis of a randomized clinical trial sug-
gests that the prognostic impact of topoisomerase IIα  gene
amplification is restricted to the patients not receiving anthra-
cycline-based chemotherapy [2]. Furthermore, other studies
that related tumor response to anthracyclines also showed
some correlation between gene amplification status of topoi-
somerase IIα  and clinical response [3-5]. This is in contrast
Table 4
Clinical characteristics of patients with and without overexpression of c-erbB2 and topoisomerase IIα
Parameter Value
Topoisomerase overexpression Absent Absent Present Present
c-erb B2 overexpression Absent Present Absent Present
Stage, n (%)
I 29 (24.2) 3 (15.0) 6 (11.1) 2 (10.0)
II 59 (49.1) 7 (35.0) 36 (66.6) 11 (55.0)
III 29 (24.2) 9 (45.0) 9 (16.7) 6 (30.0)
IV 3 (2.5) 1 (5) 3 (5.6) 1 (5.0)
Totala 120 20 54 20
Receptor status, n (%)
ER or PR positive 92 (79.3) 12 (57.1) 32 (58.2) 10 (52.6)
PR and PR negative 24 (20.7) 9 (42.9) 23 (41.8) 9 (47.4)
Totalb 116 21 55 19
a214 patients with complete data were analyzed for stage; b211 patients with complete data were analyzed for receptor status. ER, estrogen 
receptor; PR, progesterone receptor.
Figure 5
Survival of patients with and without overexpression of c-erbB2 and  topoisomerase IIα Survival of patients with and without overexpression of c-erbB2 and 
topoisomerase IIα . The difference between patients without overex-
pression of c-erbB2 or topoisomerase (broken line), patients with 
tumors overexpressing one of the two proteins (c-erbB2, dot–dashed 
line; topoisomerase IIα , solid line), and patients with tumors overex-
pressing both c-erbB2 and topoisomerase IIα  (dotted line) was signifi-
cant (log rank 29.71; P < 0.0001).Available online http://breast-cancer-research.com/content/7/3/R374
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with a recently published retrospective study in which amplifi-
cation of c-erbB2 and topoisomerase IIα  was not predictive of
the response to anthracycline [26]. Our analyses show that
the negative prognostic impact of topoisomerase IIα  protein
overexpression is observed both in patients who received an
anthracycline-containing regimen for adjuvant chemotherapy
and in those who did not. Moreover, the difference in survival
between topoisomerase IIα -positive and topoisomerase IIα -
negative patients exceeds the proportion of patients expected
to be cured by chemotherapy. Protein overexpression has
been related to a variety of other molecular markers predictive
for high proliferation rate or high grading of malignancy such
as Ki67 expression or aneuploidy [16,23,26,27]. These
findings support the view that overexpression of topoisomer-
ase IIα  protein indicates a poor prognosis irrespective of the
therapy applied. Topoisomerase IIα   gene amplification is
much more closely associated with c-erbB2 amplification than
the protein expression status (overview in [6]). The predictive
value of the gene amplification for clinical and long-term
outcome might therefore be related to amplification of either or
both of the c-erbB2 or topoisomerase IIα  genes. As coampli-
fication is the predominant mechanism of genetic alteration of
these two genes in breast cancer, clinical observations
separate the role of each gene in the clinical response to adju-
vant treatment with anthracyclines.
The biological role of topoisomerase IIα  overexpression is
unknown. Cells lacking topoisomerases II are not capable of
finishing a normal cell cycle and should therefore not be viable
[28,29]. In addition, it has been shown that experimental over-
expression of topoisomerase IIα  in different human cell lines
causes apoptosis [30]. From these observations one must
conclude that cells staining with a low intensity are not cells
with a complete lack of topoisomerase IIα  function. This is in
conformity with the observation that normal cells are also
weakly positive for topoisomerase IIα . High expression might
Table 5
Choice of the Cox regression model (N = 196)
Stepwise inclusion of variable 2 × increase in partial log-likelihood (χ 2 distributed) df P
Stage 23.43 3 < 0.0001
Estrogen receptor 7.92 1 0.005
c-erbB2 7.34 1 0.01
Topoisomerase IIα 9.85 1 0.002
Grading 0.01 1 0.92
Topoisomerase IIα  × grading 4.64 1 0.03
c-erbB2 × grading 1.74 1 0.19
c-erbB2 × topoisomerase IIα 0.17 1 0.68
Starting from the null model, successive adding of the variables mentioned above improves the Cox proportional hazard model in the first four 
steps significantly. In this sense the first four variables can be considered as independent prognostic factors. df, degrees of freedom.
Table 6
Coefficients of the linear predictor in the final Cox regression model (N = 196)
Variable B exp(B) P 95% CI for exp(B)
Stage
IIa 0.72 2.06 0.14 0.79–5.36
IIIa 1.69 5.4 0.001 1.97–14.74
IVa 3.25 25.68 <0.001 6.72–98.17
Estrogen receptor (pos. versus neg.) 0.58 1.79 0.039 1.03–3.11
c-erbB2 (pos. versus neg.) 0.82 2.26 0.0036 1.31–3.93
Topoisomerase IIα  (pos. versus neg.) 0.39 1.48 0.005 0.77–2.83
Grading (3 versus {1,2}) t0.62 0.54 0.15 0.23–1.25
Topoisomerase IIα  × gradingb 1.21 3.35 0.035 1.09–10.36
aThe hazard ratio exp(B) of the stage given is the relative risk of this stage with respect to stage I. bThe effect of the interaction term on survival can 
be described as follows: if grading equals G1 or G2, the hazard ratio of topoisomerase IIα  positive versus negative is 1.48 (95% confidence 
interval (CI) 0.77 to 2.83); if grading equals G3, this hazard ratio is 4.96 (95% CI 2.00 to 12.29).Breast Cancer Research    Vol 7 No 3    Fritz et al.
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be related to a high proliferation rate. This view is supported
by our finding that topoisomerase IIα  expression is related to
histological grading and by observations showing some corre-
lation of topoisomerase IIα  with Ki67 expression and other
proliferation markers [23,27]. However, viable cells with con-
stitutive overexpression might also indirectly indicate defects
in apoptotic pathways. Both hypotheses might provide a plau-
sible explanation for the observation that topoisomerase IIα
overexpression is related to a more aggressive tumor
phenotype.
Conclusion
Our data suggest that protein expression of topoisomerase IIα
is a prognostic factor that is independent of c-erbB2, stage,
and histological grading. In addition, the results of this explor-
atory study indicate that anthracycline treatment is not capable
of reversing the negative prognostic influence of the
expression of topoisomerase IIα  or c-erbB2. Nevertheless,
because of the small number of patients remaining in these
subgroups, no firm conclusion can be made about the predic-
tive value of topoisomerase IIα  or c-erbB2 regarding sensitivity
to anthracyclines. Our results support the view that studying
the deregulation of either the topoisomerase IIα  gene or topoi-
somerase IIα  protein might yield different results depending on
the method applied. This should be considered when planning
prospective studies on the predictive and prognostic value of
topoisomerase IIα .
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